FDAnews
www.fdanews.com/articles/61162-tissuegene-begins-trial-of-cartilage-repair-drug

TISSUEGENE BEGINS TRIAL OF CARTILAGE REPAIR DRUG

July 25, 2006

TissueGene has announced FDA acceptance of an investigational new drug application and the initiation of its Phase I clinical trial evaluating a single dose of TG-C for the treatment of degenerative joint diseases. This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty.

TissueGene has developed TG-C to regenerate cartilage in patients suffering from degenerative arthritis, more specifically for osteoarthritis of the knee. As an alternative to other methods of cartilage repair, TG-C will involve minimally invasive injections versus a surgical approach. Other techniques currently involve multiple and often invasive surgical procedures and have mixed results.